| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +66.67% | -0.53% | +0.71% | -1.24% | -2.92% | — |
| 14d | 3 | +0.00% | +5.03% | +1.36% | +3.67% | +5.72% | — |
| 30d | 3 | +0.00% | +12.52% | +1.69% | +10.83% | +15.90% | — |
| 60d | 3 | +33.33% | +2.01% | +3.27% | -1.26% | -1.32% | — |
| 90d | 3 | +0.00% | +15.76% | +2.39% | +13.38% | +13.71% | — |
| 180d | 3 | +66.67% | -19.07% | +3.19% | -22.27% | -35.01% | — |
| 1y | 3(1 pending) | +100.00% | -49.77% | +16.55% | -66.32% | -66.32% | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| JANX JANUX THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 109,900 | — | — | 109,900 | Jan 2, 2026 | Jan 2, 2026 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 31,400 | — | — | 155,825 | Jan 2, 2026 | Jan 2, 2026 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | SALE Chief Scientific Officer | 2,505 | $13.73 | $34.4K | 124,425 | Jan 2, 2026 | Jan 2, 2026 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 24,000 | — | — | 129,719 | Jan 2, 2025 | Jan 3, 2025 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 84,000 | — | — | 84,000 | Jan 2, 2025 | Jan 3, 2025 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 675 | $47.22 | $31.9K | 97,938 | Sep 27, 2024 | Sep 27, 2024 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 4,325 | $46.21 | $199.8K | 98,613 | Sep 27, 2024 | Sep 27, 2024 ↗ | View → |
| JANX JANUX THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 147,000 | — | — | 147,000 | Jan 2, 2024 | Jan 3, 2024 ↗ | View → |